Market Overview The global diabetic neuropathy market reached USD 3,775.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 6,298.1 million by 2030. The diabetic neuropathy market is expected to exhibit a CAGR of 6.7% during the forecast period (2023-2030). Diabetic neuropathy is the deterioration induced to the nerve because of diabetes, which usually causes pain and loss of sensation in the feet or lower legs. The pain can be encountered in different body parts like hips, wrists, and back based on the impact of neuropathy. There are different types of neuropathy like focal neuropathy, proximal neuropathy, peripheral neuropathy, and autonomic neuropathy. The growing number of diabetes patients and the geriatric population, and increasing funding initiatives from various government organizations are driving the global diabetic neuropathy market growth. Market Dynamics The Growing Geriatric Population is Expected to Drive The Global Diabetic Neuropathy Market Over The Forecast Period. Neuropathies are exceptionally typical in individuals over 65 years old and their preponderance upsurges with age. Thus, the growing geriatric population is driving the global diabetic neuropathy market. For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050. The Increasing Funding from Various Government Organizations is Providing the Global Diabetic Neuropathy Market with Prospective Growth Opportunities The increasing funding initiatives from various government organizations are presenting the global diabetic neuropathy market with lucrative growth opportunities. For instance, the U. S. Department of Health and Human Services, via the Indian Health Service, is funding $139 million for the Fiscal Year 2023 Special Diabetes Program for Indians (SDPI) to deliver diabetes prevention and therapy assistance for American Alaska and Indian Native communities. COVID-19 Impact Analysis The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here). Russia-Ukraine War Impact Analysis The issues that are currently being encountered by individuals with chronic conditions in Ukraine are increased by a deficiency of medical support such as medications for chronic disorders at a time when fundamental requirements like electricity, heating, and clean water are not being attended, to because of the invasion. Thus, the Russia-Ukraine war has negatively impacted the global diabetic neuropathy market. Global Recession Impact Analysis The healthcare industry is not completely invulnerable to a recession, as healthcare organizations supposed layoffs and hirings in past financial downturns. That remarked the enterprise does manage better compared to different sectors. Yet, the threat of recession risks the market as inflation succeeds. The extended degree of stress concerning the ongoing recession as the high inflation in developed countries worldwide has transpired in an all-around price ripple through the past two years. Artificial Intelligence Impact Analysis AI is anticipated to hold a positive influence on the global diabetic neuropathy market as with AI's capacity to process big data pools, combining patient experiences can direct to predictive benefits, enabling the healthcare ecosystem to expose key dimensions of patient care that need revision. Segment Analysis The global diabetic neuropathy market is segmented based on type, drug class, distribution channel, and region. The NSAIDS Segment is Estimated To Hold a 35.4% Share of the Global Market The NSAIDs segment is estimated to hold the largest share of the global diabetic neuropathy market, owing to the easy availability of the NSAIDs as are over the counter and hence, readily available for patients in their residents. Additionally, majority of the NSAIDs have their generic formulations obtainable in the market making them affordable and these drugs deliver quick relief without any severe side effects. Geographical Analysis Europe is Estimated to Hold the Second-Largest Share of the Global Diabetic Neuropathy Market During the Forecast Period Owing to the increasing incidence of diabetes, Europe is estimated to hold about 26.3% of the global diabetic neuropathy market. For instance, according to WHO, there are over 60 million individuals with diabetes in the European region, or nearly 10.3% of males and 9.6% of females aged 25 years and above. The preponderance of diabetes is rising among all generations in the European region, primarily because of the increase in overweight and obesity, unhealthy food consumption, and less physical inactivity. Competitive Landscape The major global players in the market include Depomed Pharma, Eli Lilly, Daiichi Sankyo, Teva Pharmaceutical Industries Ltd., Xenoport, Grünenthal, Johnson and Johnson, Pfizer, GlaxoSmithKline, and Boehringer Ingelheim among others. WHY PURCHASE THE REPORT? • To visualize the global diabetic neuropathy market segmentation based on type, drug class, distribution channel, and region, as well as understand key commercial assets and players. • Identify commercial opportunities by analyzing trends and co-development. • Excel data sheet with numerous data points of diabetic neuropathy market-level with all segments. • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study. • Product mapping available as Excel consisting of key products of all the major players. The global diabetic neuropathy market report would provide approximately 53 tables, 54 figures, and 195 pages. Target Audience 2023 • Manufacturers/ Buyers • Industry Investors/Investment Bankers • Research Professionals • Emerging Companies

1 Methodology and Scope 1.1 Research Methodology 1.2 Research Objective and Scope of the Report 2 Definition and Overview 3 Executive Summary 3.1 Snippet by Type 3.2 Snippet by Drug Type 3.3 Snippet by Distribution Channel 3.4 Snippet by Region 4 Dynamics 4.1 Impacting Factors 4.1.1 Drivers 4.1.1.1 Growing Cases of Diabetes 4.1.1.2 Market Developments 4.1.2 Restraints 4.1.2.1 Stringent Regulatory Authorities 4.1.3 Opportunity 4.1.4 Government Initiatives 4.1.5 Impact Analysis 5 Industry Analysis 5.1 Porter’s 5 Forces Analysis 5.2 Regulatory Analysis 5.3 Pricing Analysis 5.4 Patent Analysis 6 COVID-19 Analysis 6.1 Analysis of COVID-19 6.1.1 Scenario Before COVID-19 6.1.2 Scenario During COVID-19 6.1.3 Post COVID-19 & Future Scenario 6.2 Pricing Dynamics Amid COVID-19 6.3 Demand-Supply Spectrum 6.4 Government Initiatives Related to the Market During the Pandemic 6.5 Manufacturers’ Strategic Initiatives 6.6 Conclusion 7 Russia-Ukraine War Analysis 8 Global Recession Analysis 9 Artificial Intelligence Analysis 10 By Type 10.1 Introduction 10.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Type 10.1.2 Market Attractiveness Index, By Type 10.2 Peripheral Neuropathy 10.2.1 Introduction 10.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%) 10.3 Autonomic Neuropathy 10.4 Proximal Neuropathy 10.5 Focal Neuropathy 11 By Drug Class 11.1 Introduction 11.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class 11.1.2 Market Attractiveness Index, By Drug Class 11.2 Anti-Depressant 11.2.1 Introduction 11.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%) 11.3 Anti-Convulsant 11.4 Opioids 11.5 NSAIDs 11.6 Others 12 By Distribution Channel 12.1 Introduction 12.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel 12.1.2 Market Attractiveness Index, By Distribution Channel 12.2 Hospitals and Clinics Pharmacy 12.2.1 Introduction 12.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%) 12.3 Retail Pharmacy and Stores and Stores 12.4 Online Pharmacy 13 By Region 13.1 Introduction 13.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Region 13.1.2 Market Attractiveness Index, By Region 13.2 North America 13.2.1 Introduction 13.2.2 Key Region-Specific Dynamics 13.2.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Type 13.2.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class 13.2.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel 13.2.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 13.2.6.1 The U.S 13.2.6.2 Canada 13.2.6.3 Mexico 13.3 Europe 13.3.1 Introduction 13.3.2 Key Region-Specific Dynamics 13.3.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Type 13.3.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class 13.3.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel 13.3.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 13.3.6.1 Germany 13.3.6.2 The U.K 13.3.6.3 France 13.3.6.4 Italy 13.3.6.5 Spain 13.3.6.6 Rest of Europe 13.4 South America 13.4.1 Introduction 13.4.2 Key Region-Specific Dynamics 13.4.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Type 13.4.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class 13.4.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel 13.4.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 13.4.6.1 Brazil 13.4.6.2 Argentina 13.4.6.3 Rest of South America 13.5 Asia-Pacific 13.5.1 Introduction 13.5.2 Key Region-Specific Dynamics 13.5.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Type 13.5.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class 13.5.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel 13.5.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country 13.5.6.1 China 13.5.6.2 India 13.5.6.3 Japan 13.5.6.4 Australia 13.5.6.5 Rest of Asia-Pacific 13.6 Middle East and Africa 13.6.1 Introduction 13.6.2 Key Region-Specific Dynamics 13.6.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Type 13.6.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class 13.6.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel 14 Competitive Landscape 14.1 Competitive Scenario 14.2 Market Share Analysis 14.3 Mergers and Acquisitions Analysis 15 Company Profiles 15.1 Depomed Pharma 15.1.1 Company Overview 15.1.2 Type Portfolio and Description 15.1.3 Financial Overview 15.1.4 Key Developments 15.2 Eli Lilly and Company 15.3 Daiichi Sankyo 15.4 Teva Pharmaceutical Industries Ltd 15.5 Xenoport 15.6 Grünenthal 15.7 Johnson and Johnson 15.8 Pfizer 15.9 GlaxoSmithKline 15.10 Boehringer Ingelheim 16 Appendix 16.1 About Us and Services 16.2 Contact Us